Incidence rate
(per 100 person-years)		   Hazard ratio
(95% CI)		 P value
NOAC Reference
Apixaban vs warfarin (reference) n = 6310 n = 6310
 
    
Stroke/SE† 1.3 1.6
 
 0.72 (0.48-1.08) .113
Major bleeding‡ 4.6 7.8
 
 0.53 (0.44-0.64) <.001
Dabigatran vs warfarin (reference) n = 2342 n = 2342
 
    
Stroke/SE† 1.5 1.9
 
 0.77 (0.47-1.27) .304
Major bleeding‡ 5.7 7.4
 
 0.76 (0.56-1.04) .008
Rivaroxaban vs warfarin (reference) n = 8055 n = 8055
 
    
Stroke/SE† 1.3 1.8
 
 0.72 (0.50-1.04) .079
Major bleeding‡ 8.3 7.6
 
 1.09 (0.92-1.28) .317
0.0
0.5
1.0
1.5
2.0
Favors NOACs
Favors warfarin

No head-to-head clinical trials have been conducted comparing the efficacy and safety of DOACs versus DOACs.

Appearance of plotted data may be altered when zoom greater than 150% is applied;
refer to values in tables for context when view is zoomed.

1|2|3|4|5